However, only two of them CTLA-4 and PD-1 are primarily and broadly explored and their blockade is used as a therapeutic procedure in the routine treatment of several cancers: among others, in the treatment of advanced melanoma, non-small cell lung cancer, non-Hodgkin’s lymphoma, and kidney cancer (4). Here, PDCD1 is linked to cancer.